2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13413
    Tofogliflozin hydrate 1201913-82-7 98.48%
    Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2. Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells.
    Tofogliflozin hydrate
  • HY-20019
    L-165041 79558-09-1 99.67%
    L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
    L-165041
  • HY-114456
    Ganglioside GM3 124579-05-1 98.07%
    Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia.
    Ganglioside GM3
  • HY-129411
    Sinbaglustat 441061-33-2 ≥98.0%
    Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions.
    Sinbaglustat
  • HY-132265
    SCO-267 1656261-09-4 99.31%
    SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes.
    SCO-267
  • HY-145061
    ADAMTS-5-IN-3 2688733-96-0 98.90%
    ADAMTS-5-IN-3 (Example 37-2) is a potent inhibitor of ADAMTS-5 and ADAMTS-4 with IC50s of 8 and 12 nM, respectively. ADAMTS-5-IN-3 can be used for the research of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis.
    ADAMTS-5-IN-3
  • HY-P99357
    Crotedumab 1452387-69-7
    Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes.
    Crotedumab
  • HY-P9970A
    Infliximab (Anti-TNF-α) 99.00%
    Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
    Infliximab (Anti-TNF-α)
  • HY-117727A
    Leriglitazone hydrochloride 146062-46-6 ≥99.0%
    Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride is an orally active and a BBB-penatrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone hydrochloride, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone hydrochloride can be used in the study of neuroinflammatory and neurodegenerative diseases.
    Leriglitazone hydrochloride
  • HY-10294
    Relacatib 362505-84-8 99.99%
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo.
    Relacatib
  • HY-11029
    SNT-207707 1064662-40-3 99.51%
    SNT-207707 is a selective, potent and orally active melanocortin MC-4 receptor antagonist with an IC50 of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.
    SNT-207707
  • HY-16616
    SIRT-IN-2 1431411-66-3 98.08%
    SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 μM, respectively.
    SIRT-IN-2
  • HY-17444
    Tesaglitazar 251565-85-2 99.18%
    Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain.
    Tesaglitazar
  • HY-19779
    JTT 551 776309-04-7 99.65%
    JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with Kis of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.
    JTT 551
  • HY-19835
    LY2922470 1423018-12-5 99.11%
    LY2922470 is a selective and orally active agonist for the G protein-coupled receptor 40 (GPR40). LY2922470 activates GPR40-mediated β-arrestin recruitment with EC50s of 7 nM (human GPR40), 1 nM (mouse GPR40) and 3 nM (rat GPR40). LY2922470 can be used for research of type 2 diabetes mellitus (T2DM).
    LY2922470
  • HY-41982
    D-Glucuronic acid lactone 32449-92-6 ≥98.0%
    D-Glucuronic acid lactone (D-Glucurono-6,3-lactone) is an endogenous metabolite, which is a glucuronic acid derivative. D-Glucuronic acid lactone can be used as starting regents in the synthesis of 2,3,4,-tris(tert.-butyldimethysilyl) glucuronic acid trichloroethylester, requirement for the preparation of 1-O-acyl glucuronide of the anti-inflammatory agent ML-3000 (HY-B1452), synthesis of optically active glucopyranoses, synthesis of long-chain alkyl glucofuranosides. D-Glucuronic acid lactone is promising for research of reversible cerebral vasoconstriction syndrome (RCVS).
    D-Glucuronic acid lactone
  • HY-50861
    AZD3988 892489-52-0 ≥98.0%
    AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC50 value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity.
    AZD3988
  • HY-B0247
    Torsemide 56211-40-6 99.83%
    Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis.
    Torsemide
  • HY-B0693
    Ranitidine 66357-35-5 ≥99.0%
    Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice.
    Ranitidine
  • HY-B1429
    Chlorpropamide 94-20-2 99.79%
    Chlorpropamide is an oral hypoglycemic agent that can influence acetaldehyde metabolism in mice and has a potentiating effect on antidiuretic hormone.
    Chlorpropamide
Cat. No. Product Name / Synonyms Application Reactivity